RGCC Onco-D-clare is an advanced cancer screening test that detects cancer cells even before symptoms arise. Blending molecular biology and artificial neural networks, we empower individuals with essential insights into their cancer status. Detecting cancer early can ultimately result in improved outcomes and peace of mind for the patients
Onco-D-clare utilizes a blend of molecular biology and artificial neural networks to serve as a cancer screening test. This innovative approach enables the detection of cancer at an early stage, often before symptoms manifest.
The test has undergone clinical validation and demonstrates high accuracy, approximately 82%.
True positive rate (%) = 82.38 +/- 6.55
True negative rate (%) = 81.14+/- 5.42
Molecular biology tests let us look at the entire genetic makeup of something all at once. The qRT-PCR method is both cost-effective and quick. These methods have become more accurate, which is helpful for doctors. Plus, they can check the genetic information using blood sample, which means they don’t always need to do a painful biopsy.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
“RGCC’s Onco-D-clare test is a breakthrough in early cancer detection. Its accuracy enables timely intervention, improving patient prognosis and overall survival rates. A critical tool in cancer screening and prevention.”
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
The Onco-D-clare test can be done for individuals who have a family history of cancer or for individuals who are exposed to carcinogenic products as an occupational hazard or for any individuals who wish for cancer screening.
Onco-D-clare provides individuals with essential information to help them make better-informed decisions about future health and well-being.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Book your RGCC Onco-D-Clare screening now to identify the potential development of cancer. Empower yourself with valuable insights and start your cancer journey with RGCC Onco-D-Clare!
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media